Search results
Ozempic manufacturer Novo Nordisk launches study to find drug’s impact on reduced alcohol cravings
TheGrio via Yahoo News· 1 day agoPhoto: AdobeStock The new trial will determine whether the drug, which is approved to treat type 2...
PFF Community Registry Reaches Milestone of 2,000 Participants Impacted by Pulmonary Fibrosis and...
The Longview News-Journal· 1 day agoAchieving a significant milestone, the Pulmonary Fibrosis Foundation (PFF) Community Registry has reached 2,000 participants and counting, providing researchers with important ...
Vicore's bet pays off as pulmonary fibrosis drug improves lung function in phase 2
FierceBiotech· 2 days agoHaving stacked all its chips on the idiopathic pulmonary fibrosis (IPF) treatment buloxibutid,...
Rila Therapeutics doses first cohort in Phase I CKD treatment trial
Clinical Trials Arena via Yahoo Finance· 14 hours agoRila Therapeutics has dosed the first cohort of subjects in a Phase I clinical trial of RLA-23174, a...
Is Madrigal Pharmaceuticals Stock a Buy?
Motley Fool via Yahoo Finance· 11 hours agoMDGL data by YCharts An important approval -- with an asterisk NASH affects 1.5 million people in the U.S. It is caused by a dangerous buildup of fat in...
Why Early Diagnosis of Cystic Fibrosis Can Be Life Extending
Medscape· 7 days agoJessica Hane, MD: Today we're going to hit the highlights from our recent podcast on cystic fibrosis...
Summit: R.I. has all the ingredients to develop a successful life science industry
Providence Business News· 8 hours agoWhen Robert Coughlin was running for a seat in the Mass. House of Representatives he was hit with a...
Endeavor BioMedicines' ENV-101 improves lung function and reverses fibrosis in IPF patients
BioPharma-Reporter· 4 days agoThe treatment showed improved lung function and reversed lung fibrosis in idiopathic pulmonary ...
... Trial of RLA-23174, a First-In-Class HIPK2 Allosteric Inhibitor, For Treatment of Chronic Kidney...
FOX 5 San Diego· 1 day agoRLA-23174 is a first-in-class small molecule allosteric inhibitor of HIPK2 which inhibits TGF-β signaling to address FSGS and other fibrotic diseases. RLA-23174 is a new small molecule allosteric ...
GRI Bio reports progress in IPF treatment with GRI-0621 By Investing.com
Investing.com· 1 day agoThe data, presented in San Diego between May 17-22, 2024, indicates that GRI-0621, a selective...
